# US 2006/0155115 A1 · Multivalent T cell receptor complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0155115 A1
- Document ID: US20060155115A1
- Status: Published application
- Kind: A1
- Application number: 11/321,894
- Filed: 2005-12-29
- Published: 2006-07-13
- Earliest claimed: 1998-05-19
- Assignees: Avidex Limited
- Inventors: Bent Jakobsen; Jonathan Boulter
- Web page: https://patentgrep.com/patent/US20060155115A1

## CPC

- G01N 33/56977: {HLA or MHC typing}
- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a synthetic multivalent T cell receptor complex for binding to a MHC-peptide complex, which multivalent T cell receptor complex comprises a plurality of T cell receptors specific for the MHC-peptide complex. It is preferred that the T cell receptors are refolded recombinant soluble T cell receptors. The synthetic multivalent T cell receptor complex can be used for delivering therapeutic agents or for detecting MHC-peptide complexes, and methods for such uses are also provided.

## Claims

### Claim 1

A synthetic multivalent T cell receptor (TCR) complex for binding to a MHC-peptide complex, which TCR complex comprises a plurality of T cell receptors specific for the MHC-peptide complex, wherein each TCR in the complex is a refolded recombinant TCR which comprises:
i.) a recombinant TCR α or γ chain extracellular domain having a first C-terminal dimerization peptide which is heterologous to the α or γ chain; and
ii.) a recombinant TCR β or δ chain extracellular domain having a second C-terminal dimerization peptide which is heterologous to the β or δ chain and which is specifically heterodimerized with the first heterodimerization peptide to form a heterodimerization domain,
wherein a disulfide bond present in native TCRs between the α and β or γ and δ chains adjacent to the cytoplasmic domain is absent from the recombinant TCR.

### Claim 2 (depends on 1)

The TCR complex according to claim 1, wherein the T cell receptors are αβ T cell receptors having an α chain and a β chain.

### Claim 3 (depends on 2)

The TCR complex according to claim 2, wherein the α chain and β chain are soluble forms of T cell receptor α and β chains.

### Claim 4 (depends on 1)

The TCR complex according to claim 1, wherein the T cell receptors are in the form of multimers of two or more T cell receptors.

### Claim 5 (depends on 4)

The TCR complex according to claim 4, wherein the multimer is a trimer or a tetramer.

### Claim 6 (depends on 1)

The TCR complex according to claim 1, wherein the T cell receptors are associated with one another via a linker molecule.

### Claim 7 (depends on 6)

The TCR complex according to claim 6, wherein the linker molecule is a multivalent attachment molecule.

### Claim 8 (depends on 7)

The TCR complex according to claim 7, wherein at least one of the T cell receptor α or β chains is derived from a fusion protein comprising an amino acid sequence encoding a protein tag.

### Claim 9 (depends on 8)

The TCR complex according to claim 8, wherein the T cell receptors are biotinylated.

### Claim 10 (depends on 1)

The TCR complex according to claim 1, comprising a multimerized recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer.

### Claim 11

A multivalent TCR complex comprising a multimerized recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer, wherein each TCR in the complex is a refolded recombinant TCR which comprises:
i) a recombinant TCR α or γ chain extracellular domain having a first C-terminal dimerization peptide which is heterologous to the α or γ chain; and
ii) a recombinant TCR β or δ chain extracellular domain having a second C-terminal dimerization peptide which is heterologous to the β or δ chain and which is specifically heterodimerized with the first dimerization peptide to form a heterodimerization domain,
wherein a disulfide bond present in native TCRs between the α and β or γ and δ chains adjacent to the cytoplasmic domain, is absent from the recombinant TCR.

### Claim 12 (depends on 11)

The TCR complex according to claim 11, wherein the heterodimerization domain is a coiled coil domain.

### Claim 13 (depends on 12)

The TCR complex according to claim 12, wherein the dimerization peptides are c-jun and c-fos dimerization peptides.

### Claim 14 (depends on 11)

The TCR complex according to claim 11, comprising a flexible linker located between the T cell receptor chains and the heterodimerization peptides.

### Claim 15 (depends on 1)

The TCR complex according to claim 1, wherein the T cell receptor is expressed in an E. coli expression system.

### Claim 16 (depends on 1)

The TCR complex according to claim 1, wherein the T cell receptor is biotinylated at the C-terminus.

### Claim 17 (depends on 1)

The TCR complex according to claim 1, wherein the T cell receptors are associated with a lipid bilayer.

### Claim 18 (depends on 17)

The TCR complex according to claim 17, wherein the lipid bilayer forms a vesicle.

### Claim 19 (depends on 18)

The TCR complex according to claim 18, wherein the T cell receptors are attached at the exterior of the vesicle.

### Claim 20 (depends on 18)

The TCR complex according to claim 18, wherein the T cell receptors are attached to the vesicle via derivatized lipid components of the vesicle.
